PMID- 34733921
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220428
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 9
IP  - 17
DP  - 2021 Sep
TI  - LncRNA FTX promotes the malignant progression of colorectal cancer by regulating 
      the miR-214-5p-JAG1 axis.
PG  - 1369
LID - 10.21037/atm-21-2755 [doi]
LID - 1369
AB  - BACKGROUND: Long non-coding RNAs (lncRNAs) have recently been found to be vital 
      regulators of various cancers, including colorectal cancer (CRC). It has been 
      previously reported that the dysregulated expression of lncRNA Five prime to Xist 
      (FTX) is involved in carcinogenesis. However, the role of lncRNA FTX in the 
      progression of CRC is still unclear. METHODS: Fluorescence in situ hybridization 
      (FISH) was used to detect the expression of lncRNA FTX and miR-214-5p in CRC 
      tissues. Cell Counting Kit-8 assay, transwell assay, wound-healing assay, and 
      proliferation assay were used to explore the function of lncRNA FTX in CRC cells. 
      Quantitative real-time polymerase chain reaction (qRT-PCR), western blotting, and 
      luciferase reporter assay were used to confirm the relationship between lncRNA 
      FTX and miR-214-5p-jagged canonical Notch ligand 1 (JAG1). We further explored 
      the role of lncRNA FTX in vivo using xenograft tumor assay. RESULTS: lncRNA FTX 
      was found to be upregulated in CRC tissues by FISH. The downregulation of 
      endogenous lncRNA FTX expression inhibited CRC cell proliferation, migration, and 
      invasion. Mechanistically, lncRNA FTX sequestered miR-214-5p and thus released 
      its repression on JAG1, driving the malignant progression of CRC. CONCLUSIONS: 
      These findings give rise to a new perspective, the lncRNA FTX-miR-214-5p-JAG1 
      regulatory axis, in exploring the cancer-promoting mechanism of lncRNA FTX in 
      CRC.
CI  - 2021 Annals of Translational Medicine. All rights reserved.
FAU - Pan, Luxiang
AU  - Pan L
AD  - State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, 
      Fourth Military Medical University, Xi'an, China.
FAU - Du, Mingrui
AU  - Du M
AD  - Department of Orthopedics, Tangdu Hospital, Fourth Military Medical University, 
      Xi'an, China.
AD  - School of Basic Medicine, Fourth Military Medical University, Xi'an, China.
FAU - Liu, Haixia
AU  - Liu H
AD  - Department of Gynecology and Obstetrics, Shandong Provincial Hospital Affiliated 
      to Shandong First Medical University, Jinan, China.
FAU - Cheng, Boyang
AU  - Cheng B
AD  - School of Basic Medicine, Fourth Military Medical University, Xi'an, China.
FAU - Zhu, Maorong
AU  - Zhu M
AD  - School of Basic Medicine, Fourth Military Medical University, Xi'an, China.
FAU - Jia, Bo
AU  - Jia B
AD  - Department of Neurosurgery, Xijing Hospital, Fourth Military Medical University, 
      Xi'an, China.
FAU - Wang, Yinwen
AU  - Wang Y
AD  - School of Basic Medicine, Fourth Military Medical University, Xi'an, China.
FAU - He, Wei
AU  - He W
AD  - State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, 
      Fourth Military Medical University, Xi'an, China.
FAU - Li, Xiaoju
AU  - Li X
AD  - State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, 
      Fourth Military Medical University, Xi'an, China.
FAU - Liu, Chenlin
AU  - Liu C
AD  - State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, 
      Fourth Military Medical University, Xi'an, China.
FAU - Gu, Jintao
AU  - Gu J
AD  - State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, 
      Fourth Military Medical University, Xi'an, China.
FAU - Li, Meng
AU  - Li M
AD  - State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, 
      Fourth Military Medical University, Xi'an, China.
FAU - Zhang, Yingqi
AU  - Zhang Y
AD  - State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, 
      Fourth Military Medical University, Xi'an, China.
FAU - Yao, Li
AU  - Yao L
AD  - Department of Pathology, Xi'an No. 3 Hospital, The Affiliated Hospital of 
      Northwest University, Xi'an, China.
FAU - Zhang, Yi
AU  - Zhang Y
AD  - State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, 
      Fourth Military Medical University, Xi'an, China.
FAU - Hao, Qiang
AU  - Hao Q
AD  - State Key Laboratory of Cancer Biology, Biotechnology Center, School of Pharmacy, 
      Fourth Military Medical University, Xi'an, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC8506562
OTO - NOTNLM
OT  - colorectal cancer (CRC)
OT  - lncRNA FTX
OT  - miR-214-5p
OT  - progression
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at https://dx.doi.org/10.21037/atm-21-2755). The authors have no 
      con fl icts of interest to declare.
EDAT- 2021/11/05 06:00
MHDA- 2021/11/05 06:01
PMCR- 2021/09/01
CRDT- 2021/11/04 06:28
PHST- 2021/05/27 00:00 [received]
PHST- 2021/07/19 00:00 [accepted]
PHST- 2021/11/04 06:28 [entrez]
PHST- 2021/11/05 06:00 [pubmed]
PHST- 2021/11/05 06:01 [medline]
PHST- 2021/09/01 00:00 [pmc-release]
AID - atm-09-17-1369 [pii]
AID - 10.21037/atm-21-2755 [doi]
PST - ppublish
SO  - Ann Transl Med. 2021 Sep;9(17):1369. doi: 10.21037/atm-21-2755.